BIO Comments on the Indian DOP Report on Price Negotiation of Patented Drugs

We understand the challenges that India faces with respect to healthcare and the innovative biotechnology industry stands ready to work with India to help address them.<br />

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

BIO’s members recognize the needs of Indian patients who have limited or no access to health and medicines in particular. We applaud the efforts of the Central Government, as well as some states, to purchase and provide at low-cost or no-cost essential medicines to its citizens with limited means. Moreover, BIO recognizes that innovation in the biotechnology sector may hold the answer to many of India’s challenges.

Thus, it is important for the Government of India to develop policies that address the needs of Indian patients without hindering the ability of innovative companies to develop and produce the medicines that patients around the world need. In doing so, it is essential that the costs and benefits of such proposed policies be carefully assessed. We respectfully submit the comments below with this perspective in mind.

Click through for full BIO Comments on DOP Patented Drug Pricing Report